Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CorMedix Inc (CRMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: CRMD (5-star) is a REGULAR-BUY. BUY since 36 days. Profits (7.02%). Updated daily EoD!
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
6 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Year Target Price $16.83
Year Target Price $16.83
| 3 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 65.06% | Avg. Invested days 35 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 847.81M USD | Price to earnings Ratio 50 | 1Y Target Price 18.83 |
Price to earnings Ratio 50 | 1Y Target Price 18.83 | ||
Volume (30-day avg) - | Beta 1.61 | 52 Weeks Range 3.61 - 17.43 | Updated Date 06/29/2025 |
52 Weeks Range 3.61 - 17.43 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.25 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 20.81% | Operating Margin (TTM) 51.5% |
Management Effectiveness
Return on Assets (TTM) 8.31% | Return on Equity (TTM) 19.87% |
Valuation
Trailing PE 50 | Forward PE 17.73 | Enterprise Value 770782026 | Price to Sales(TTM) 10.27 |
Enterprise Value 770782026 | Price to Sales(TTM) 10.27 | ||
Enterprise Value to Revenue 9.34 | Enterprise Value to EBITDA 43.63 | Shares Outstanding 67824704 | Shares Floating 67090118 |
Shares Outstanding 67824704 | Shares Floating 67090118 | ||
Percent Insiders 1.19 | Percent Institutions 37.17 |
Analyst Ratings
Rating 4.5 | Target Price 16.83 | Buy 3 | Strong Buy 3 |
Buy 3 | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
CorMedix Inc
Company Overview
History and Background
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infections and inflammatory diseases. Founded in 2006, the company has focused on its lead product candidate, DefenCath, to reduce catheter-related bloodstream infections.
Core Business Areas
- DefenCath Development: Focuses on the development and potential commercialization of DefenCath, a catheter lock solution designed to prevent catheter-related bloodstream infections (CRBSIs) in hemodialysis patients.
Leadership and Structure
CorMedix is led by a management team with experience in biopharmaceuticals. The company has a board of directors overseeing its strategic direction.
Top Products and Market Share
Key Offerings
- DefenCath: DefenCath (taurolidine and heparin) is a catheter lock solution for the prevention of catheter-related bloodstream infections (CRBSIs) in hemodialysis patients. The primary competitors include antibiotic lock solutions. There is no established market share for DefenCath as it has yet to be approved by the FDA.
Market Dynamics
Industry Overview
The market involves the prevention and treatment of infections in various healthcare settings, particularly bloodstream infections associated with medical devices. There is a growing awareness of the economic and clinical burden of such infections, driving demand for effective prevention strategies.
Positioning
CorMedix is positioned as a company aiming to address a significant unmet need in preventing CRBSIs. Its competitive advantage lies in the potential of DefenCath to offer a non-antibiotic approach to infection prevention.
Total Addressable Market (TAM)
The estimated TAM for CRBSI prevention in hemodialysis patients is estimated to be in the hundreds of millions of dollars annually. CorMedix, with DefenCath, is positioned to capture a significant portion of this market upon approval and successful commercialization.
Upturn SWOT Analysis
Strengths
- Novel non-antibiotic approach
- Potential to reduce antibiotic resistance
- Addresses a significant unmet need
- Focus on a specific market segment
Weaknesses
- Reliance on a single product candidate
- Regulatory approval risk
- Commercialization challenges
- Limited financial resources
Opportunities
- Expansion into other catheter-related infection indications
- Partnerships with healthcare providers
- Geographic expansion
- Potential for government funding
Threats
- Regulatory setbacks
- Competition from existing and new products
- Pricing pressures
- Changes in healthcare guidelines
Competitors and Market Share
Key Competitors
- MLND
- BMRN
Competitive Landscape
CorMedix faces competition from companies developing alternative infection prevention strategies. Its advantage lies in its unique non-antibiotic approach. Market share data represents current treatment options in the market that are not non-antibiotic
Growth Trajectory and Initiatives
Historical Growth: CorMedix's historical growth has been characterized by research and development activities with no significant product revenue.
Future Projections: Future growth is projected to come from the potential commercialization of DefenCath. Analyst estimates depend heavily on regulatory approval and market adoption.
Recent Initiatives: Recent initiatives include completing clinical trials for DefenCath, preparing for regulatory submissions, and establishing manufacturing and distribution partnerships.
Summary
CorMedix is a high-risk, high-reward biopharmaceutical company heavily reliant on the success of its lead product candidate, DefenCath. The company's future is largely dependent on securing FDA approval and successfully commercializing DefenCath. While the non-antibiotic approach offers a competitive advantage, regulatory setbacks and commercialization challenges pose significant risks. Investors should closely monitor clinical trial results, FDA decisions, and market adoption rates.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Market share information is based on current market data and estimations.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CorMedix Inc
Exchange NASDAQ | Headquaters Berkeley Heights, NJ, United States | ||
IPO Launch date 2010-03-25 | CEO & Director Mr. Joseph Todisco MBA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 64 | Website https://www.cormedix.com |
Full time employees 64 | Website https://www.cormedix.com | ||
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.